Who
MPM BIOVENTURES 2018, L.P.
10% owner
Company insider
Files Form 4 as: 10% owner, Entrada Therapeutics; 10% owner, Aktis Oncology; 10% owner, iTeos Therapeutics.
In numbers
- Trades disclosed
- 44
- Buys
- 2
- Sells
- 24
- Bought
- $22.0M
- Sold
- $9.6M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 7 Sep 2021
- Last trade
- 9 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 9 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $206K28,837 at $7.13 | filing |
| 8 Sep 2026filed 9 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M192,500 at $7.41 | filing |
| 4 Sep 2026filed 9 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $274K38,500 at $7.11 | filing |
| 3 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $231K32,263 at $7.17 | filing |
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $181K25,131 at $7.19 | filing |
| 1 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $205K29,088 at $7.06 | filing |
| 31 Aug 2026filed 31 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $309K44,259 at $6.99 | filing |
| 28 Aug 2026filed 31 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K3,733 at $7.01 | filing |
| 27 Aug 2026filed 31 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $280K38,922 at $7.20 | filing |
| 26 Aug 2026filed 26 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K14,569 at $7.06 | filing |
| 25 Aug 2026filed 26 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $200K26,522 at $7.54 | filing |
| 24 Aug 2026filed 26 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $159K21,623 at $7.34 | filing |
| 12 Jan 2026filed 14 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —1,314,262 | filing |
| 12 Jan 2026filed 14 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —5,914,197 | filing |
| 12 Jan 2026filed 14 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code C | —1,577,119 | filing |
| 12 Jan 2026filed 14 Jan 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Bought | $20.0M1,112,777 at $18.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,000,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —22,500,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —6,000,000 at $0.00 | filing |
| 7 Dec 2021filed 7 Dec 2021 | iTeos Therapeutics | SEC FORM 4 Sold | $595K17,962 at $33.15 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastAKTS · dailypolitical.com · 19 Oct 2026Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyTRDA · manilatimes.net · 14 Oct 2026Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)TRDA · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name MPM BIOVENTURES 2018, L.P.; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.